Novartis to acquire Tourmaline Bio for $1.4 billion Sep 9, 2025 01:00AM
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) Sep 9, 2025 01:00AM